Phase 2/3 of the DRAGON II trial will evaluate the efficacy, safety, and tolerability of Tinlarebant in approximately 60 adolescent...
PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on...
Lean Loss Ratio of only 21.9%, representing class-leading preservation of lean mass Maintenance of lean mass preservation in individuals over...
MORRISTOWN, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment...
MELBOURNE, Australia and PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage...
SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing...
Ms. Thompson Brings Nearly 25 Years of HR Leadership Driving Top Performing Cultures and Building Exceptional TeamsCHASKA, Minn., Sept. 10,...
ANN ARBOR, Mich., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for...
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the...
WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing...
TFF-dry powder HA antigen vaccine candidates induced neutralizing antibody titers in ferrets against H1 and H3 influenza strains Ongoing funded...
2.5 mg dose restored normative wakefulness with mean sleep latency of 32 minutes as measured by the Maintenance of Wakefulness...
Thomas brings more than 20 years of commercial and operations experience in the biopharmaceutical industry to Tonix Tonix is on...
Milestone Results in $8 Million Payment to C4 Therapeutics WATERTOWN, Mass., Sept. 10, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc....
- Statistically Significant and Clinically Meaningful Efficacy Data with Favorable Benefit/Risk ratio from DUBLIN-3 Phase 3 Study of Plinabulin plus...
Full clinical data will be reported in an oral presentation at the premier global event for advancements in cardiovascular science...
VANCOUVER, BC / ACCESSWIRE / September 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased...
Trisha Pfluger, M.S., PMP, Chief Scientific Officer, and Nicholas Totagrande, CEO, Juno Biomedical, Inc. talk medical advancement, AI, and next...
DALLAS, Sept. 9, 2024 /PRNewswire/ -- Scout, a leader in innovative services and technology, proudly introduces ecoScout, a first-in-market solution for...
TAMPA, Fla., Sept. 9, 2024 /PRNewswire/ -- WellSync, a leader in telehealth innovation, is excited to announce a collaboration with...